Federal Supply Schedule 36F79724D0185

Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., holds a Federal Supply Schedule (FSS) contract (36F79724D0185) with the U.S. Department of Veterans Affairs (VA) to supply pharmaceutical products, primarily the enzyme replacement therapy Galafold (migalastat) for the treatment of Fabry disease. This multiple-award, firm-fixed-price FSS contract, valued at $13,024,630, has a period of performance through August 31, 2029 and falls under the Pharmaceuticals and Drugs (FSS-61-IB) schedule. Various VA Veterans Integrated Service Networks (VISNs) have placed task orders against this FSS contract to procure Galafold for their respective regions, including the Philadelphia, Pennsylvania area. The task orders, which range from approximately $18,000 to $63,000, support the VA's mission to provide specialized healthcare services and medications to veterans across the country, ensuring continuous access to critical treatments for rare diseases like Fabry disease. No set-aside designations have been applied to these contract awards.

The information provided indicates that Amicus Therapeutics US, LLC consistently fulfills emergency pharmacy orders and regular supply requests for Galafold to various VA healthcare facilities and service networks. These firm-fixed-price delivery orders demonstrate the company's role in supporting the VA's pharmaceutical needs and ensuring veterans have access to the enzyme replacement therapy Galafold for the treatment of Fabry disease, a rare genetic disorder. The contract awards do not specify any additional products or services beyond the supply of Galafold, though the parent company Amicus Therapeutics, Inc. may engage in broader federal contracting and grant activities as a development stage biopharmaceutical company.